Abaloparatide Completed Phase 2 Trials for Postmenopausal Osteoporosis Treatment

Back to Abaloparatide
IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01674621Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis